BMS, Nordic Bioscience to Develop Biomarkers for NASH, Fibrotic Diseases
Bristol-Myers Squibb (BMS) and Nordic Bioscience said today they will partner to develop biomarker technology for diagnosis and monitoring of nonalcoholic steatohepatitis (NASH) and other fibrotic diseases. Un…
Read guide →